000K utf8 1100 $c2024 1500 eng 2050 urn:nbn:de:gbv:8:3-2026-01033-7 2051 10.1038/s41375-024-02375-8 3000 Khouja, Mouhamad 3010 Alig, Stefan K. 3010 Darzentas, Nikos 3010 Dreyling, Martin 3010 Gonzalez de Castro, David 3010 Hermine, Olivier 3010 Hoster, Eva 3010 Jiang, Linmiao 3010 Klapper, Wolfram 3010 Kluin-Nelemans, Hanneke C. 3010 Pal, Karol 3010 Pott, Christiane 3010 Regmi, Binaya 3010 Schwarz, Martin 3010 Stewart, Peter James 4000 Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials$hSpringer Science and Business Media LLC [Khouja, Mouhamad] 4030 $nSpringer Science and Business Media LLC 4209 Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We conducted a comprehensive genomic characterization of 180 patients from the European MCL network trials by targeted sequencing of peripheral blood DNA using the EuroClonality(EC)-NDC assay. The IGH::CCND1 fusion was identified in 94% of patients, clonal IGH-V-(D)-J rearrangements in all, and 79% had ≥1 somatic gene mutation. The top mutated genes were ATM, TP53, KMT2D, SAMHD1, BIRC3 and NFKBIE. Copy number variations (CNVs) were detected in 83% of patients with RB1, ATM, CDKN2A/B and TP53 being the most frequently deleted and KLF2, CXCR4, CCND1, MAP2K1 and MYC the top amplified genes. CNVs and mutations were more frequently observed in older patients with adverse impact on prognosis. TP53mut, NOTCH1mut, FAT1mut TRAF2del, CDKN2A/Bdel and MAP2K1amp were linked to inferior failure-free (FFS) and overall survival (OS), while TRAF2mut, EGR2del and BCL2amp related to inferior OS only. Genetic complexity (≥3 CNVs) observed in 51% of analysed patients was significantly associated with impaired FFS and OS. We demonstrate that targeted sequencing from peripheral blood and bone marrow reliably detects diagnostically and prognostically important genetic factors in MCL patients, facilitating genetic characterization in clinical routine. 4950 https://doi.org/10.1038/s41375-024-02375-8$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2026-01033-7$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00008540 5051 610 5550 Adult 5550 Aged 5550 Aged, 80 and over 5550 Biomarkers, Tumor 5550 DNA Copy Number Variations 5550 Female 5550 Genetic Testing 5550 High-Throughput Nucleotide Sequencing 5550 Humans 5550 Lymphoma, Mantle-Cell 5550 Male 5550 Middle Aged 5550 Mutation 5550 Prognosis 5550 Risk Factors